Longboard Pharmaceuticals, Inc. (LBPH)

$4.7

+0.44 (+10.33%)
Rating:
Recommendation:
-
Symbol LBPH
Price $4.7
Beta 0.000
Volume Avg. 0.02M
Market Cap 80.912M
Shares () -
52 Week Range 2.7-6.474
1y Target Est -
DCF Unlevered LBPH DCF ->
DCF Levered LBPH LDCF ->
ROE -68.60% Strong Sell
ROA -74.88% Strong Sell
Operating Margin -
Debt / Equity 11.97% Neutral
P/E -
P/B 1.12 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest LBPH news


Mr. Kevin R. Lind
Healthcare
Biotechnology
NASDAQ Global Market

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.